Butantan Institute
Clinical trials sponsored by Butantan Institute, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Dengue vaccine trial aims to protect seniors Results expected Mar 2027 (estimated)
- One shot, two protections? new trial combines dengue and chikungunya vaccines Results expected Jul 2027 (estimated)
- New H5N8 bird flu vaccine enters human trials Results expected Aug 2027 (estimated)
-
Chikungunya vaccine shows promise for teens in landmark trial
Vaccine CompletedThis study tested a single-dose chikungunya vaccine (VLA1553) in about 750 teenagers aged 12 to 17. The goal was to see if the vaccine safely produces enough antibodies to protect against the virus. Participants received either the vaccine or a placebo, and their immune responses…
Phase 3 • Sponsor: Butantan Institute • Aim: Vaccine
Last updated Jun 27, 2026 13:02 UTC
-
Brazilian flu vaccine put to the test against global standard
Vaccine CompletedThis completed Phase 4 trial tested whether the Butantan Institute's seasonal flu vaccine is as safe and effective as the Sanofi vaccine. A total of 632 Brazilian adults aged 18 to 69 received one of the two vaccines. Researchers measured immune response through blood tests and t…
Phase 4 • Sponsor: Butantan Institute • Aim: Vaccine
Last updated Jun 27, 2026 12:32 UTC
-
New dengue vaccine shows promise in Head-to-Head trial
Vaccine CompletedThis study tested a new dengue vaccine called V181 against an existing one (Butantan-DV) in 1,364 healthy adults aged 18 to 50 in Brazil. The goal was to see if V181 is as safe and triggers a similar immune response. Results showed V181 was safe and produced comparable antibody l…
Phase 2 • Sponsor: Butantan Institute • Aim: Vaccine
Last updated Jun 27, 2026 07:57 UTC
-
New quadrivalent flu vaccine shows promise for kids under 3
Vaccine CompletedThis completed Phase 3 trial tested a quadrivalent (four-strain) influenza vaccine from Instituto Butantan in over 1,300 healthy infants and children aged 6 to 35 months. The study compared the immune response and safety of two doses (0.25ml and 0.50ml) against standard trivalent…
Phase 3 • Sponsor: Butantan Institute • Aim: Vaccine
Last updated Jun 26, 2026 19:13 UTC